[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018更新版). 中华肝脏病杂志,2018, 26:188-194.
[2] Yannaki E , Athanasiou E , Xagorari A et al. G-CSF-primed hematopoietic stem cells or G-CSF per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs . Exp Hematol,2005,33: 108-119.
[3] Simonetto DA, Shah VH, Kamath PS.Improving survival in ACLF: growing evidence for use of G-CSF. Hepatol Int, 2017,11:473-475.
[4] Spahr L, Chalandon Y, Terraz S et al.Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease:a randomized controlled trial.PLoSOne, 2013,8:e53719
[5] Thursz MR, Richardson P, Allison M et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med, 2015,372:1619-1628.
[6] Singh S, Osna NA, Kharbanda KK.Treatment options for alcoholic and non-alcoholic fatty liver disease: a review. World J Gastroenterol, 2017,23:6549-6570.
[7] Garg V , Garg H , Khan A et al. Granulocyte-colony stimulating factor mobilizes CD34+ cells and improves survival of patients with acute-on-chronic liver failure.Gastroenterology, 2012,142:505-512.
[8] Godfrey EL, Stribling R, Rana A.Liver transplantation for alcoholic liver disease: an Update. Clin Liver Dis, 2019,23:127-139.
[9] Gaia S, Smedile A, Omedè P et al.Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease. J Hepatol, 2006,45:13-19.
[10] Cho Y, Park YS, Kim HY et al,efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response tosteroid (GRACIAH trial): study protocol for a randomized controlled trial.. Trials, 2018,22,19:696.
[11] Di Campli C, Zocco MA, Saulnier N et al,Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure. Dig Liver Dis, 2007,39:1071-1076.
[12] Duan XZ, Liu FF, Tong JJ et al. Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol, 2013,21,19:1104-1110.
[13] 杨昊臻,郑楠楠,胡瑾华. 重组人粒细胞集落刺激因子的免疫调节作用及其在肝衰竭中的应用.中华肝脏病杂志,2013, 21:718-720.
[14] Spahr L , Chalandan Y , Terraz S et al. Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial. PLoS One,2013,8: e53719.
[15] 马玉杰, 梁辉. 重组人G-CSF治疗不同白细胞减少症的疗效与机制. 上海交通大学学报(医学版),2009, 29: 1081-1084.
[16] 王亚东,马路园,季茹,等.粒细胞集落刺激因子在肝衰竭治疗中的作用机制及其临床应用研究进展. 中华内科杂志, 2017, 56:954-957. |
